Trial Profile
A nested case-control study of dabigatran, apixaban, and rivaroxaban
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2020
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- 05 Feb 2020 Results published in the British Journal of Clinical Pharmacology
- 20 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management